MethylGene Initiates Phase II Clinical Trial With Its Proprietary HDAC Inhibitor, MGCD0103, In High-Risk Myelodysplastic Syndromes ‘MDS’ And Acute Myelogenous Leukemia ‘AML’

MONTREAL, QUEBEC--(CCNMatthews - Dec. 7, 2006) - MethylGene Inc. (TSX:MYG), along with its partner Pharmion Corporation (NASDAQ:PHRM) today announced the initiation of a Phase II clinical trial with its isotype-specific histone deacetylase (HDAC) inhibitor product candidate, MGCD0103, in patients with high-risk myelodysplastic syndromes (MDS) or relapsed or refractory acute myelogenous leukemia (AML). Specific patient populations include elderly patients who have previously untreated disease or adult patients who have relapsed or refractory disease.